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Abstract
Fragile X syndrome (FXS) is the most common single gene cause of intellectual disability and it is 
characterized by a CGG expansion of more than 200 repeats in the FMR1 gene, leading to 
methylation of the promoter and gene silencing. The fragile X premutation, characterized by a 55 
to 200 CGG repeat expansion, causes health problems and developmental difficulties in some, but 
not all, carriers. The premutation causes primary ovarian insufficiency in approximately 20% of 
females, psychiatric problems (including depression and/or anxiety) in approximately 50% of 
carriers and a neurodegenerative disorder, the fragile X-associated tremor ataxia syndrome 
(FXTAS), in approximately 40% of males and 16% of females later in life. Recent clinical studies 
in premutation carriers have expanded the health problems that may be seen. Advances in the 
molecular pathogenesis of the premutation have shown significant mitochondrial dysfunction and 
oxidative stress in neurons which may be amenable to treatment. Here we review the clinical 
problems of carriers and treatment recommendations.
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Introduction
Fragile X premutation carriers are identified by an expanded trinucleotide (CGG) expansion 
in the 5’ untranslated region of the FMR1 gene. In the past, research mainly focused on the 
individuals with the full mutation with fragile X syndrome (FXS) and carriers were thought 
to be unaffected. In the last 20 years, our knowledge of clinical involvement in premutation 
carriers has expanded to a broad range of neurological, neurocognitive, endocrine and 
psychiatric problems related to RNA toxicity [1, 2]. This review will focus on disorders 
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related to the premutation and recommendations for treatment. The premutation is common 
in the general population and approximately 1 in 130 to 250 women and 1 in 250–810 males 
have the premutation [3–5].
FMRP, the protein produced by the FMR1 gene, is important in embryonic development, 
including the differentiation and migration of neurons and glia cells, for regulation of 
synaptic plasticity throughout life and for adult neurogenesis [6–9]. FMRP is also critical for 
normal connectivity with an appropriate balance of excitatory (glutamate) and inhibitory 
(GABA) circuits [10, 11]. In the absence of FMRP there is a deficit of GABAA activity [12] 
and up-regulation of the metabotropic glutamate receptor 5 (mGluR5) pathway leading to 
enhanced long term depression (LTD) of synaptic connections [13]. Hays et al. [14] have 
demonstrated a prolonged neocortical UP (depolarized firing of neurons) state in FXS 
mouse that is rescued by mGluR5 antagonists. FMRP also regulates presynaptic release of 
neurotransmitters. When it is absent or deficient, there is enhanced release which leads to 
problems in detecting subtle changes in synaptic stimulation [15]. Those with the full 
mutation have little or no FMRP, whereas the levels of FMRP in carriers of the premutation 
correlates inversely with CGG repeat number [16, 17]. Most carriers have normal levels of 
FMRP but those with a premutation above 120 can have significant deficits of FMRP [16–
21].
The premutation is associated with significant up-regulation (2 to 8 times normal) of the 
FMR1 mRNA that correlates directly with CGG repeat number [22]. Elevated FMR1 mRNA 
leads to a process of RNA toxicity which is thought to be the main cause of clinical 
involvement in premutation carriers [23]. The excess FMR1 mRNA contains the expanded 
repeats that form hairpin loops which are sticky and sequester proteins that are needed for 
normal neuronal function (including Sam 68, DROSHA and DGCR8) [23–25]. The elevated 
FMR1 mRNA and the sequestered proteins lead to the formation of inclusions in neurons, 
astrocytes, and peripheral nervous system and tissue including the adrenals, testes, pancreas, 
heart, and other organs [26–28].
The development of the knock-in premutation mouse has allowed further studies of the 
neuronal dysregulation that occurs in carriers. The premutation mouse also develops 
inclusions and neurological symptoms with aging [29]. There is a deficit of GABA 
inhibition noted in the mice and also in females with the premutation through transcranial 
magnetic stimulation (TMS) studies [12, 30]. In premutation neuron cultures, the dendritic 
tree is less complex with fewer synaptic connections [31]. The mitochondria also have 
slower movement within dendrites and axons [32] and the neurons have enhanced spikes 
[33] compared to controls.
There is evidence that both mild deficits of FMRP and the RNA toxicity of elevated FMR1 
mRNA can contribute to the phenotype of premutation carriers [1]. Recent studies have 
shown that FMRP levels may vary in the general population in those that do not have an 
FMR1 mutation [34]. Keri and Benedek [35] studied typical individuals and found that the 
level of FMRP correlates with studies of visual contrast sensitivity and perception, such that 
those with a higher level of FMRP have better visual perceptual abilities. Wang et al [36] 
found that the size of cortical structures correlated with FMRP levels in those without a 
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fragile X mutation. Recently, in those with schizophrenia, it has been found that the age of 
onset and the IQ correlated with the level of FMRP in blood [34, 37]. Fatemi and colleagues 
[38, 39] have found that various neuropsychiatric disorders including depression, bipolar 
disorder, autism, and schizophrenia have a deficit of FMRP in the brain.
Seizures can be deleterious for development and early life seizures in rats without an FMR1 
mutation have been shown to shift FMRP away from the dendritic spines and into the 
perinuclear area leading to FMRP dysfunction at the synapse [40]. These findings emphasize 
the need to treat seizures as early as possible so that the levels of FMRP in the dendrites can 
be sustained. Seizures in boys with the premutation have been associated with the 
development of autism spectrum disorder (ASD) [41]. Therefore both the molecular findings 
(CGG repeats, FMRP and FMR1 mRNA) and environmental experiences such as seizures or 
exposures to toxins may influence the early development and aging of carriers (Figure 1).
FXPOI and FXTAS
In 1991 Cronister et al [42] discovered an increased prevalence of premature ovarian failure 
(POF; menopause before age 40) in females with the premutation that has been confirmed 
by many others. This condition is now called fragile X-associated primary ovarian 
insufficiency (FXPOI) [43–45]. FXPOI occurs in approximately 20% of carriers, whereas 
cessation of periods before age 45 occurs in an additional 20% [46].
Ten years later in 2001, the fragile X-associated tremor ataxia syndrome (FXTAS) was 
reported in older male carriers [47] followed by a report of FXTAS in females with the 
premutation [48].
FXTAS is characterized by intention tremor, ataxia leading to frequent falling, peripheral 
neuropathy, autonomic dysfunction including hypertension, orthostatic hypotension, and 
cognitive decline [49, 50]. The cognitive problems begin with executive function and short 
term memory deficits and then gradual cognitive decline occurs, sometimes leading to 
dementia, particularly in males [51–54]. FXTAS is also characterized by generalized brain 
atrophy and white matter disease in the periventricular and subcortical regions in addition to 
the middle cerebellar peduncles (MCP sign) [55]. More recent reports have shown thinning 
of the corpus callosum with white matter disease in the splenium, pons and insula [1, 56, 
57].
The diagnostic criteria for FXTAS were described after the original patients were reported 
[49]. The original diagnostic guidelines for FXTAS based on clinical reports were later 
expanded to include characteristic FXTAS eosinophilic intranuclear inclusions that are seen 
in neurons and astrocytes throughout the brain of individuals with FXTAS [28, 48, 58]. The 
onset and trajectory of the cognitive problems FXTAS is similar to that of Alzheimer 
Disease (AD), and, in fact, may benefit from research into treatments for AD [59, 60] or 
other neurodegenerative diseases such as Parkinson’s disease (PD). Neuropathological 
studies of those with FXTAS have shown the common co-morbidity of FXTAS, AD and PD 
suggesting that FXTAS may stimulate the onset of these other aging diseases [1, 59].
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Expanding the Premutation Clinical Picture
We now realize that premutation clinical involvement includes many more conditions than 
FXTAS or FXPOI alone. In those carriers that have mild deficits of FMRP [20] there may 
be features of FXS, including prominent ears or more significant deficits in executive 
function [61, 62] and visuospatial perception, [35, 63],[64, 65]. There are working memory 
deficits in the premutation carriers both with and without FXTAS [36, 61, 66–68].
Studies of the brain of the premutation mouse models have demonstrated deficits of FMRP 
throughout the brain [69–71]. The dual mechanism of involvement, of high FMR1 mRNA 
and low FMRP is considered a double hit, including features of FXS and premutation 
involvement. The phenotype of these individuals is somewhat different from typically 
affected males with FXS because a mild deficit of FMRP usually causes only mild 
developmental problems so that these individuals have a higher IQ, and less severe 
behavioral problems than those with full mutation FXS [36, 61, 66–68].
In a national survey study of over 1,276 families who have children with either the full 
mutation or the premutation, Bailey et al [72] found a high rate of co-morbidity in boys with 
the premutation. The problems that were significantly different from their non-fragile X 
brothers included autism in 19.3%, attention problems in 41%, seizures in 11.3%, 
developmental disabilities in 33%, and anxiety in 33% of the premutation brothers. Similar 
results were seen by Farzin et al [73] who studied premutation proband brothers who 
presented clinically compared to premutation brothers who were identified by cascade 
testing and brothers without the premutation. There was a significantly higher rate of autism, 
ASD, and ADHD in the probands compared to the other two groups. However, nonproband 
brothers also had an increase in social deficits compared to the non-premutation brothers. In 
a subsequent study by Chonchaiya et al [41], boys with the premutation had a higher rate of 
seizures than controls and the presence of seizures correlated with the presence of ASD. 
This study suggests that the occurrence of seizures will further interfere with the 
connectivity of the brain in young carriers and make ASD a more likely outcome. Therefore, 
early identification and treatment of seizures is a priority in premutation carriers and in those 
with FXS [74, 75], because seizures can further reduce the available FMRP levels in 
dendrites [40].
The emotional problems of carriers have been well studied [76–81]. Females with the 
premutation have been found to have higher rates of mood disorders than the general 
population, [82] and those with FXTAS have higher rates of major depressive disorder, 
panic disorder, post-traumatic stress disorder, and specific phobia compared to the general 
population [83]. Carriers without FXTAS have higher rates of social phobia compared to the 
general population [83]. These problems are thought to be related to RNA toxicity in the 
amygdala and hippocampus. MRI imaging has demonstrated that the size of the 
hippocampus directly correlates with the level of anxiety in females with the premutation 
who have not developed FXTAS [84]. Therefore, the higher the anxiety level, the smaller 
the hippocampus suggesting that long term stress and anxiety in carriers is deleterious to the 
brain. In female carriers, there is a correlation of CGG repeats, cortisol level, negative life 
events and the risk for the development of emotional problems [2, 81].
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Additional medical problems that are common in carriers, particularly aging carriers with 
neurological problems or FXTAS, include hypothyroidism (50% of females) [85], 
fibromyalgia (43% of females) [85], sleep apnea [86], migraine headaches [87], Restless 
Legs syndrome [88], fatigue [89] and hypertension [90]. Regular screening for 
hypothyroidism, hypertension, migraines, and sleep apnea are recommended because these 
problems also require treatment and can interfere with brain function if untreated. Olfaction 
deficits with FXTAS can also cause quality of life issues for premutation carriers [91].
Sleep apnea may often start before the onset of other neurological problems with FXTAS 
[86]. Therefore, we recommend that all individuals with FXTAS or neurological symptoms 
be tested for sleep apnea, since the hypoxia generated by sleep apnea may further exacerbate 
the MRI abnormalities seen in carriers including the white matter disease. Hypertension is 
significantly increased in FXTAS compared to controls and this may also be exacerbated by 
sleep apnea. Treatment of hypertension is also a necessity in premutation carriers because 
uncontrolled hypertension can also lead to further CNS dysfunction including progression of 
white matter disease and brain atrophy [86, 92].
MRI studies of Premutation Carriers
Work by Hessl and Rivera has advanced our understanding of the molecular underpinnings 
of CNS dysfunction causing problems in carriers who do not have FXTAS. In their study of 
23 young adult male carriers (mean age 32.9 years), compared to age-matched controls, they 
found a significantly smaller left and right amygdala volume and a significant decrease in 
the right amygdala activation in an emotion matching task [93]. The molecular parameters 
of lowered FMRP levels and the elevated FMR1 mRNA levels correlated significantly with 
the decreased activation of the amygdala, but FMRP was the most significant molecular 
factor in these correlations [93]. Additional MRI studies by Hashimoto et al have shown 
significant grey matter reduction in the anterior subregions of the cerebellar vermis and 
hemispheres [94]. Additionally, in carriers without FXTAS, as compared to age-matched 
controls, display decreased activation in the right ventral inferior frontal cortex and in the 
left premotor dorsal inferior frontal cortex on fMRI [95]. The problems in the frontal cortex 
may relate to the executive function and memory deficits seen in some premutation carriers 
who do not have FXTAS [61, 95]. On DTI studies, there are significant elevations in the 
axial diffusivity and in the radial diffusivity in the MCP area in carriers without FXTAS 
compared to age-matched controls [96] in addition to some connectivity loss [97]. A study 
by Apartis et al. describes corpus callosum splenium hyperintensities as being as frequent as 
the MCP hyperintensities, especially in female carriers [50].
These changes in the MRI studies on brain structure and function in carriers compared to 
controls are present in young adults and therefore likely represent long term effects of RNA 
toxicity in addition to mild deficits of FMRP. It is uncertain which, if any, of these deficits 
will predict the development of FXTAS, which occurs in 40 % of male carriers and up to 
16.5% of female carriers [77, 78, 85, 98]. Typically, the onset of FXTAS occurs in the early 
60s, with tremor and then ataxia [54], but, on occasion, FXTAS may present with cognitive 
decline initially [54, 99]. However, when FXTAS emerges, the abnormalities in white 
matter are apparent on a clinical reading of the MRI. Battistella et al [100] have noted 
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significant decreases in gray matter in the cerebellar and hippocampal areas of 
asymptomatic premutation carriers as young as twenty years old (average age of 47) and 
also that a later onset of diffuse white matter disease may serve as a marker for imminent 
FXTAS onset [100]. These signs indicate a long progression towards FXTAS and offer hope 
for a wider window during which treatments may be effective [36, 101].
Premutation Neurons in Culture
Chen et al. [31] have studied premutation mouse neurons in culture compared to neurons 
without the premutation. The complexity of the dendritic tree was reduced and stress 
proteins were increased in the premutation neurons compared to controls. The premutation 
neurons would die more easily in culture with a significant increase in the death rate by 21 
divisions. Additional morphological differences include reduced postsynaptic density 
protein 95 (PSD 95) expression, reduced synaptic puncta density, and reduced neurite length 
[102]. Premutation neurons are also functionally abnormal as clustered spontaneous calcium 
oscillations have been observed with amplitudes increased over normal [102, 103]. 
Premutation cells in culture are hyper-responsive to glutamate in that intracellular calcium 
concentrations remained elevated after exposure [102]. These findings suggest that 
premutation neurons are more vulnerable to toxicity or stressful conditions in culture, and 
this has been seen in clinical cases who have enhanced neurological problems when exposed 
to toxins such as chemotherapy [104] or environmental toxins [105]. Smoking is another 
toxin that can negatively impact premutation cells. Smoking in females with the premutation 
can significantly lower the age of FXPOI compared to non-smokers [106]. The premutation 
neurons demonstrate enhanced oxidative stress and a rise in heat shock proteins (including α 
B crystallin and dysregulation of lamin A/C) [31, 107]. These findings suggest that 
treatment with antioxidants would help premutation neurons and cellular studies are 
underway to assess this effect. Because of the known oxidative stress, we recommend 
treatment with antioxidants in carriers as described below (Figure 2).
Mitochondrial Dysfunction and FMR1 RNA Toxicity
The toxicity that excessive FMR1 mRNA levels cause in premutation cells may be related to 
several factors. The dysregulation of lamin A/C is significant, and distortions of nuclear 
structure can be seen in fibroblasts, neurons and even embryonic cells [107, 108]. The 
binding and sequestration of DROSHA and DGCR8 can lead to microRNA (miRNA) 
dysregulation [24]. These two proteins are critical for miRNA maturation, and when they are 
depleted, related to sequestration, there is dysregulation of the miRNA levels, which are 
important control elements for most of the activities of the cell. Dysregulation of several 
miRNA levels have been found those with FXTAS [25, 109]. Additionally, in the 
Drosophila model of FXTAS, the activation of specific retrotransposons can modulate 
neurodegeneration [110]. The intrinsic mis-folding and aggregation tendencies of FMR1 
RNA has also been suggested as a possible mechanism in the pathology of the 
neurodegeneration associated with FXTAS [111]. A recent report of RAN translation in 
those with FXTAS can lead to the development of toxic levels of polyglycine [112]. 
Premutation hippocampal neurons have reduced mobility and higher rates of basal oxygen 
consumption and proton leakage in mouse models [32].
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There are also abnormalities of mitochondrial functions related to transport problems of 3 
nuclear encoded proteins into the mitochondria in carriers both with and without FXTAS 
[113, 114]. The brain’s dependence on oxidative phosphorylation of glucose for ATP makes 
this especially important in neural tissues. In addition to iron dysregulation and deposition, 
defective zinc bioavailability and/or transport may be related to this mitochondrial 
dysfunction [114]. This problem can be compounded with environmental stress and/or 
toxins leading to even more impairment [114]. This is especially problematic as stress 
mRNAs appear to accumulate in the nucleus of cells, and may be linked to 
neurodegeneration [115]. Deficits in mitochondrial function are also seen in autism [116] 
and in other neurodevelopmental disorders in addition to some neurodegenerative disorders 
including PD and AD [117, 118].
The premutation has been seen in a limited number of other neurodegenerative diseases such 
as PD [56]. In fact, some cases of PD are nearly indistinguishable from cases of FXTAS 
[119]. The use of L-DOPA, deep brain stimulation and other treatments for PD may prove 
helpful for carriers [60, 120].
FXTAS in Gray Zone and in Unmethylated Full Mutation Carriers
The original diagnostic criteria for FXTAS state that the premutation is necessary for the 
diagnosis [49]. However, recent reports have documented FXTAS in individuals with a gray 
zone CGG repeat expansion (45–54 CGG repeats) [121, 122]. In the Liu et al paper, grey 
zone individuals with tremor and balance problems were in families known to have 
individuals with FXTAS related to the premutation. Since FXTAS can cluster in families, 
there may be additional genetic predisposing or protective factors. One report has found that 
an ApoE4 allele, which predisposes to AD, is also associated with FXTAS [123]. Loesch et 
al [124] have demonstrated that the gray zone shows elevated FMR1 mRNA compared to 
the general population. Thus, it is likely that the elevation in FMR1 mRNA is sufficient to 
induce FXTAS through FMR1 mRNA toxicity. However, since the gray zone is very 
common in the general population (approximately 1 in 30) most individuals with a gray 
zone do not develop FXTAS.
Those individuals with an unmethylated full mutation can also develop FXTAS because 
they have elevated FMR1 mRNA. The first case was first reported by Loesch et al. [125] 
and this patient was affected by substance abuse (alcoholism). This patient met all of the 
criteria of FXTAS including the MCP sign and cognitive decline. It is possible that his 
alcoholism also predisposed him to FXTAS. We have also seen an unmethylated mosaic 
patient who presented with a neurodegenerative condition that was diagnosed as PD [121] 
but, on autopsy, FXTAS inclusions were seen, and he demonstrated the clinical features of 
FXTAS [126]. Even though these cases may be rare, they suggest that the definition of 
FXTAS should be extended to include those with a gray zone and an unmethylated full 
mutation.
Toxins and Anesthesia
The issue of exacerbation of the molecular dysregulation in fragile X premutation carriers by 
environmental toxins requires further research [127]. Work in autism has implicated a broad 
Polussa et al. Page 7






















group of toxins including insecticides, pesticides, polychlorinated biphenyls (PCBs), fire 
retardants, mercury and others [127–132]. Organophosphate pesticides can interfere with 
acetylcholine and GABA neurotransmission. PCBs and related non-coplanar structures such 
as triclosan, a common antibacterial, can also activate the ryanodine receptor and mobilize 
Ca+2, which disrupts signaling and effects both neurodevelopment and neurodegeneration 
[128]. Recent work by Wolstenholme et al [133] has demonstrated transgenerational 
disruption of mRNA levels in the brain leading to social deficits related to bisphenol A 
exposure in mice. These toxins are likely to exacerbate the clinical picture in both 
premutation carriers and full mutation patients with FXS.
Anesthesia and surgery can also lead to neurotoxicity in the general population, particularly 
for children who have had multiple surgeries [134, 135] and for more vulnerable populations 
such as those with AD [136]. In AD, biomarkers for neuroinflammation are increased in 
cerebrospinal fluid after anesthesia [136]. Amyloid β production and tau phosphorylation are 
increased as well [136]. Premutation carriers, particularly those with FXTAS, are also a 
vulnerable population, and we have seen the onset of FXTAS symptoms following a 
prolonged surgery, particularly in those who are 60 years old and older [1]. However, these 
cases are anecdotal. There is a need for large-scale studies to understand the link between 
general anesthesia and the development of FXTAS. Even so, avoidance of prolonged 
general anesthesia, when possible, is recommended for older carriers, particularly if 
neurological symptoms or FXTAS are present.
Drugs of abuse are another source of toxins. In our experience, premutation carriers who 
abuse drugs often have faster progression of their FXTAS symptoms. Heroin, cocaine, 
methamphetamine, and marijuana induce oxidative stress in neurons [137–143]. The use of 
drugs and/or excessive alcohol is common in carriers [144, 145], perhaps in an effort to 
selfmedicate and improve ADHD symptoms, anxiety, and chronic pain caused by 
neuropathy even prior to FXTAS. However, there may be a biological drive related to 
elevation of mGluR5 that modulates alcohol self-administration and relapse behavior, 
potentially allowing for treatment with acamprosate [146, 147].
Animal studies suggest that the oxidative stress related to drugs of abuse can be reversed by 
antioxidants [137, 148]. Methamphetamine abuse leads to very significant neurotoxicity 
relating to a long lasting glial response with an increase in the number of astrocytes, release 
of inflammatory mediators, production of reactive oxygen species (ROS), and an increase in 
the blood brain barrier permeability through modification of the tight junctions [138]. 
Methamphetamine abuse augments dopamine levels and dopamine removal by auto-
oxidation or monoamine oxidase, leads to the production of ROS. Some of these changes 
can be improved by antioxidants as described below [137, 139, 148].
Opioids are also concerning because they can lead to exacerbation of white matter disease, 
yet many premutation carriers are prescribed these drugs because of pain symptoms related 
to neuropathy or fibromyalgia. In animal models, opioid use has been shown to cause brain 
damage across a broad range of doses [149] and induces cell death through mitochondrial 
dysfunction [150]. Similar compounds that act on opioid receptors, such as methadone, 
should also be avoided due to similar effects [151, 152].
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Alcohol is especially important to avoid in excess. Chronic excessive alcohol consumption 
can cause neuroinflammation, brain damage, and disrupts myelination [153, 154]. Alcohol 
consumption also decreases white matter integrity [155], potentially complementing a 
decline into FXTAS as seen in the Loesch et al case [125]. Although red wine, in 
moderation may protect against neurodegeneration (due to the neuroprotective effects of 
resveratrol [156], excessive alcohol consumption should be avoided.
Treatment Implications for Premutation Carriers
A significant question that arises on a regular basis in clinic is what can be done to reduce 
the risk of developmental problems and aging problems in individuals with the premutation. 
While longitudinal studies have not yet been done to investigate this issue, current molecular 
finding (including enhanced molecular stress and mitochondrial dysfunction as described 
above) suggest the use of treatments proven in similar conditions may be beneficial. 
Additionally, premutation carriers may be proactive about treating other quality of life 
aspects of global health impacted by the premutation (such as anxiety or stress) (Figure 2), 
especially as it has been suggested that there exists a limited developmental window during 
which intervention would be most effective [157].
Medical Interventions
Although no medication has been found to block or reverse FXTAS so far, new research has 
opened possibilities of medical interventions to help mitigate some of the problems with the 
premutation throughout the lifespan. Interventions are being studied now to lower the excess 
FMR1 mRNA, but they are not available clinically yet [23]. A controlled trial of memantine 
to block glutamate toxicity exacerbated by glutamate abnormalities in carriers [103] was not 
shown to be efficacious for the tremor, balance or executive function deficits in FXTAS 
[158]. However, ERP studies have shown improvement in brain-language processing in 
those with FXTAS treated with memantine compared to controls, so there may be some 
minimal cognitive improvements in processing information [159]. Allopregnanolone, a 
natural neurosteroid, has shown some benefit to the mouse model of premutation. When 
administered to premutation neurons in culture, allopregnanolone mitigated functional 
impairments observed in premutation neurons in a reversible manner [33]. The use of an 
mGluR5 antagonist (MPEP) was also helpful to the premutation neurons, suggesting that 
this category of targeted treatments for FXS may be helpful in FXTAS.
When depression or anxiety are present, selective serotonin reuptake inhibitors (SSRIs) are 
recommended, and their effect is usually beneficial [160]. SSRIs not only increase serotonin 
levels, but they also stimulate neurogenesis [161–163] through increased levels of BDNF 
[164]. This may be helpful in FXTAS individuals who have significant brain atrophy [60]. 
Encouraging neurogenesis may facilitate prevention and treatment of depression as well 
[162, 163].
Antioxidants
Based on animal studies or human studies on disorders similar to the premutation, there are 
a variety of antioxidants that are likely to be helpful in reversing the oxidative stress of 
Polussa et al. Page 9






















neurons with the premutation (Table 1). In newborn KO mice, de Diego-Otero et al 
demonstrated that treatment with alpha-tocopherol (vitamin E), in addition to N acetyl –L 
cysteine (NAC), normalized synaptic connections and rescued aspects of the physical and 
cognitive/ behavioral phenotype [165]. Additional studies have linked vitamin E to 
improvements in dementia associated with AD as well as generalized mild cognitive 
impairments common with age [166, 167]. Chronic pharmacological treatment with 
alphatocopherol (Vitamin E) in fragile X mice has been shown to alleviate free radical 
overproduction, and reduce oxidative stress [165]. The same study also showed improved 
behavior and reversed learning deficits [165]. Vitamin E and other vitamins are likely 
helpful for premutation carriers as well. However, further studies of these antioxidants have 
not been carried out in patients with the premutation.
Melatonin is another antioxidant where use in FMR1 knockout mice normalized glutathione 
levels compared to controls [168]. Melatonin has also shown to improve context-depended 
exploratory and anxiety behaviors and learning abnormalities [168]. Melatonin has also 
shown to be an effective sleep aid in individuals with FXS [169]. As sleep disturbances are 
very common in individuals with the premutation, particularly in carrier daughters of men 
who have FXTAS [170], earlier and longer sleep may significantly improve quality of life 
for premutation carriers. Melatonin, while effective for sleep, is also effective in preventing 
oxidative stress in models of PD and AD [171]. Melatonin is also unique in that it is 
selectively taken up by mitochondrial membranes [171] which may enhance its protective 
action in the premutation.
Folic acid is an antioxidant that has been studied for years in individuals with FXS [173, 
174]. It has a minimal psychotropic effect in some controlled studies, although the reason 
for this effect is not known. It is clearly important for aging because folic acid, combined 
with vitamin B12, lowers homocysteine levels. This combination reduces brain atrophy in 
typically aging individuals and also in those with mild cognitive impairment (MCI) [175]. 
Since brain atrophy is a severe problem in older premutation carriers with FXTAS, we 
routinely recommend treatment with folic acid and vitamin B 12 in older carriers to lower 
homocysteine levels.
Coenzyme Q10 (CoQ10) acts as an electron carrier in the electron transport chain of 
mitochondria and appears to have antioxidant effects. CoQ10 deficiencies have been 
documented in diseases similar to FXTAS such as PD and AD [178, 193]. Although more 
studies are needed, widespread preliminary data shows that CoQ10 have shown encouraging 
data results in treating neurological disorders such as Alzheimer, Parkinson, Friedrich and 
Huntington diseases [176–180, 194].
Other antioxidants that may prove beneficial to premutation carriers include ginseng and 
ginsenosides. Korean Red Ginseng has been shown to protect mitochondria from damage, 
prevent cell death during iron-induced oxidative stress, [181] and also to prevent 
neuroinflammation associated with neurodegeneration [182]. In mice, ginseng shows a 
fluoxetine-like anti-depressant effect and regulates synaptic plasticity proteins (including 
BDNF) to prevent cognitive decline associated with aging [183, 184].
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Omega 3 fatty acids also have a protective function against oxidative stress. Human studies 
show reduced oxidative stress and damage [185]. Omega 3s increase superoxide dismutase 
activity in rats [186] where it is also shown that induced oxidative stress is compensated for 
through daily doses of omega 3s [187].
Anecdotally, patients with FXTAS have commented on beneficial effects of L-Arginine. 
There are some studies in rats that support a protective effect of L-Arginine against 
oxidative stress [195], however this, in addition to other antioxidants, have not been studied 
in premutation carriers.
Glutathione is also an essential cofactor for glutathione peroxidase, which acts as an 
antioxidant enzyme in the cell. Deficits of glutathione peroxidase cause additional oxidative 
stress in cells. Anthocyanin class compounds are effective in reducing the iron based lipid 
peroxidation and overall levels of oxidative stress in cells [192]. Additionally, anthocyanins 
significantly enhance glutathione peroxidase activity in cell-free assays [192].
Epigallocatechin-3-gallate (EGCG), found in green tea, is another potent antioxidant whose 
antioxidant effects in-vivo are well known [188–190, 196]. Consumption of green tea has 
been shown to alleviate age-related neuro-degeneration and boost cognitive function and 
would thus likely be helpful for FXTAS [189, 191, 196].
A study by Bowman et al [197] analyzed plasma biomarkers as a measure of nutritional 
quality. Higher levels of plasma vitamins and marine omega 3 fatty acids were linked to 
higher cognitive ability and higher brain volume with aging. Conversely, the study found 
that higher levels of trans-fats were linked to lower cognitive ability and reduced brain 
volume [197]. This evidence suggests that such changes in diet may be helpful for FXTAS 
with aging also.
While each of these vitamins and antioxidants have shown significant protection against 
oxidative stress, none have been studied specifically in premutation carriers with or without 
FXTAS. There is a need for such studies. Although these interventions are not likely to 
reverse FXTAS, they may be important, along with other lifestyle changes, to stall, delay, or 
avoid the onset of FXTAS in carriers.
Stress reduction
Raising a child with FXS, taking care of someone with FXTAS, or other significant 
involvement from the premutation is stressful to parents and to the family [80, 198]. Animal 
models of the premutation have also shown increased stress and cortisol elevations with age 
[199]. Mindfulness based stress reduction has been studied for reducing stress in cases of 
long term conditions with psychological distress and well-being issues such as cancer [200], 
multiple sclerosis [201], fibromyalgia [202] and rheumatoid arthritis [203] and have yielded 
positive results. Fibromyalgia is common in female premutation female carriers with age 
and the prevalence rises to 43% if neurological problems/FXTAS are present [85, 204]. 
Mindfulness stress reduction is a mental training to develop awareness and acceptance skills 
to cope with daily events that otherwise cause heightened elevated stress. Mindfulness 
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meditation has been shown to reduce anxiety, improve mood, and increase brain GABA 
levels [205].
Relaxation is a process that decreases the effects of stress and supports stress management. 
Beneficial effects of relaxation techniques include: slowing heart and breathing rate, 
lowering blood pressure, increased blood flow, reduced muscle tension and pain, and 
improved concentration. The National Center for Complementary and Alternative Medicine 
(NCCAM) published an overview about relaxation techniques for health [206].
Bio and neurofeedback treatments for relaxation and other behavioral interventions have 
been reported on for over 30 years [207]. Biofeedback and neurofeedback provides specific 
information about internal biological processes (i.e. muscle activity, respiration, heart rate 
variability, skin temperature and brain electrical activity) in an individual. Depending upon 
the physiological processes targeted, healthier patterns of activity can be achieved by most 
people after they have participated in 10 to 50 sessions of biofeedback or neurofeedback 
supported with professional coaching and practice. For example, Thompson, Thompson and 
Reid [208] described that effective neurofeedback plus biofeedback for individuals with 
Asperger disorder included several 50-minute sessions of neurofeedback twice weekly. Ten 
to fifteen of these sessions combined neurofeedback with biofeedback of other physiological 
parameters, such as heart rate variability, respiration, or electrodermal activity, if an initial 
assessment suggested that the individual experienced difficulties sustaining alertness or 
heightened anxiety. The therapists also guided individuals to practice and generalize these 
skills to daily activities. Further, once the individual achieved a relaxed, calm and focused 
state during the feedback training, they were also trained to maintain this state while 
performing mental activities designed to improve their cognitive processes (e.g., emotional 
comprehension in listening).
The 2011 study by Prinsloo et al. [209] showed an improvement in cognitive performance in 
healthy male volunteers (aged 23 to 41 years old) after the use of a short duration heart rate 
variability (HRV) biofeedback intervention with the StressEraser, a handheld portable HRV 
biofeedback device (StressEraser TM, Helicor, USA). Various biofeedback protocols [210] 
and assistive electronic technologies such as the NeXus-10, emWave Personal Stress 
Reliever® or StressEraser® exist to enhance the balance of parasympathetic activity, vagal 
tone, increase HRV and synchronize respiration with the heart rhythm (i.e., the slowing 
down and speeding up of the heart over time). The emWave® Coherence System by 
HeartMath is one example that has an emerging evidence base for its efficacy with children 
[211, 212]. Although these techniques have not been studied in premutation carriers with or 
without FXTAS, the need is great, and they are worthy of future investigations.
Exercise, Cognitive training, and Neurogenesis
To complement the use of antioxidants to protect against oxidative stress, exercise may also 
prove beneficial. Among regularly exercising older men, there is a marked decrease in 
vascular endothelial oxidative stress [213]. This likely holds true for brain tissue as well. A 
separate study by Shanely et al finds overall lower levels of inflammation and oxidative 
stress in adults who are physically fit and regularly active [214, 215]. Furthermore, 
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Traustadottir et al have found that exercise helps to blunt the body’s hypothalamicpituitary-
adrenal (HPA) axis response to psychological stress [216].
Exercise offers other benefits as well. Physical exercise increases adult neurogenesis and 
telomerase activity [161, 217, 218]. Telomeres are shorter in carriers compared to controls, 
which exercise would likely improve [219]. Exercise in rats boosts immune and 
neuroimmune cytokines [218]. Exercise also increases the size and plasticity of the 
hippocampus and improves memory [220, 221]. Although exercise increases the levels of 
brain-derived neurotrophic factor (BDNF) it appears that the increase in hippocampus size is 
independent of BDNF levels [215, 221]. Exercise in the mouse model of schizophrenia 
improves behavioral deficits [217]. Exercise also reduces feelings of depression perhaps by 
increasing serotonin levels [222]. A daily regimen of resistance training can also increase 
general cognition [223] and produces a shift in mitochondrial DNA that dilutes mutational 
burdens associated with aging [224]. Even brief bouts of activity increased levels of 
mitochondria in cells and helps cope with stress [225].
Several studies have shown beneficial effects of cognitive training to improve cognitive 
abilities [226, 227]. Cognitive training can be computer-based, and it typically involves a 
guided practice of standard tasks to reflect areas of cognition, such as memory, attention, or 
executive function.
Conclusions
The premutation is common in the general population and it can be associated with both 
developmental problems in addition to neurological and psychiatric problems with aging. 
The molecular underpinnings of premutation involvement are known and treatment for 
specific difficulties including ASD, anxiety, and depression often responds well to the use of 
an SSRI and counseling/ therapy. Prophylactic intervention with antioxidants, exercise, 
mindfulness meditation and avoidance of toxins has been anecdotally helpful, although 
controlled studies are needed to judge efficacy. This issue is complex because it is unclear 
why some individuals with the premutation have developmental and aging problems, 
whereas others do not. The reasons are likely related to both environmental and genetic 
effects. Treatments outlined here may offer some benefit for premutation carriers.
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General model of aging in FMRl premutation carriers. Normal aging processes, like 
telomere shortening, gerontogenesis etc., are exacerbated by FMRl toxicity across the whole 
lifespan of a premutation carrier.
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Recommendations and treatments to support healthy aging and support for FMRl 
premutation carriers including medications, complementary and alternative treatment 
methods, and lifestyle changes as evidenced by similar neurodegenerative disorders.
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Table 1
Antioxidant for fragile X premutation carriers as evidenced by their use in similar population.
Substance Outcome Study Population Reference
Alpha Tocopherol (Vitamin E) Normalization of synaptic connections FMR1 KO Mouse [165]
Improvements in dementia Alzheimer disease [166, 167]
Reduction of oxidative stress FMR1 KO Mouse [165]
Melatonin Glutathione level normalization FMR1 KO Mouse [168]
Improvement of anxiety and learning abnormalities FMR1 KO Mouse [168]
Sleep Aid Children with fragile X [169]
Women with the premutation [170]
Reduction of oxidative stress Parkinson disease [171, 172]
Folic Acid (Vitamin B9) Lowers homocysteine levels Fragile X [173, 174]
Reduced brain atrophy with age Typically aging individuals [175]
CoEnzyme Q10 Global symptoms (UPDRS Score –Unified Parkinson’s 
Disease Rating Scale)
Parkinson Disease [176, 177]
Cognitive Function Alzheimer Disease [178]
Overall energy level Friedreich Ataxia [179]
Early tremor symptoms Huntington Disease [180]
Ginseng Reduction of oxidative stress Cell cultures [181]
Reduction of neuroinflammation Mice [182]
Mood Mice [183]
Memory Mice [184]
Omega 3s Improved antioxidant activity Humans [185]
Rats [186, 187]
Epigallocatechin-3-gallate (EGCG) Reduction of oxidative stress Cell cultures [188–190]
Humans [189]
Rats [191]
Anthocyanins Reduction of oxidative stress Cell cultures [192]
N acetyl–L cysteine Normalization of synaptic connections FMR1 KO Mouse [165]
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